Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome
International Journal of Cancer · 15.02.2025 · 156 (4) · 776-787
DOI: 10.1002/ijc.35199 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, online erschienen am 25.09.2024. Verfasst von Marcel Wiesweg und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oligometastatic (OMD) non‐small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches is lacking, in particular with respect to the integration of immunotherapy. This real‐world study identified 218 patients with OMD NSCLC (2004–2023, prespecified criteria: ≤5 metastases in ≤2 organ systems) from three major German comprehensive cancer centers. Most patients had one (72.5%) or two (17.4%) metastatic lesions in a single (89.9%) organ system. Overall survival (OS) was significantly longer with a single metastatic lesion (HR 0.54, p = .003), and female gender (HR 0.4, p < .001). Median OS of the full cohort was 27.8 months, with 29% survival at 5 years. Patients who had completed LAT to all NSCLC sites, typically excluding patients with early progression, had a median OS of 34.4 months (37.7% 5‐year OS rate) with a median recurrence‐free survival (RFS) of 10.9 months (13.3% at 5 years). In those patients, systemic treatment as part of first‐line therapy was associated with doubling of RFS (12.3 vs. 6.4 months, p < .001). Despite limited follow‐up of patients receiving chemo‐immunotherapy (EU approval 2018/2019), RFS was greatly improved by adding checkpoint inhibitors to chemotherapy (HR 0.44, p = .008, 2‐year RFS 51.4% vs. 15.1%). In conclusion, patients with OMD NSCLC benefitted from multimodality approaches integrating systemic therapy and local ablation of all cancer sites. A substantial proportion of patients achieved extended OS, suggesting a potential for cure that can be further augmented with the addition of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen-Ruhrlandklinik, University Duisburg-Essen, Essen, Germany.
- Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany.
- Institute of Pathology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Institute for Artificial Intelligence in Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Clinic for Internal Medicine I, University Hospital, Technische Universität Dresden, Dresden, Germany.
ORCID-Profile: Marcel Wiesweg, Wilfried Eberhardt, Albrecht Stenzinger, Michael Thomas
Zitieren
APA
Wiesweg, M., Küter, C., Schnorbach, J., Keyl, J., Metzenmacher, M., Cvetkovic, J., Saalfeld, F. C., Glanemann, F., Eberhardt, W., Oezkan, F., Theegarten, D., Stenzinger, A., Darwiche, K., Koschel, D., Herth, F., Bölükbas, S., Winter, H., Weykamp, F., Wermke, M., …, & Christopoulos, P. (2025). Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome. International Journal of Cancer, 156(4), 776-787. https://doi.org/10.1002/ijc.35199
Vancouver
Wiesweg M, Küter C, Schnorbach J, Keyl J, Metzenmacher M, Cvetkovic J, et al. Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome. International Journal of Cancer. 2025;156(4):776-787. doi:10.1002/ijc.35199
BibTeX
@article{Wiesweg2025,
author = {Wiesweg, Marcel and Küter, Claudia and Schnorbach, Johannes and Keyl, Julius and Metzenmacher, Martin and Cvetkovic, Jelena and Saalfeld, Felix Carl and Glanemann, Franziska and Eberhardt, Wilfried and Oezkan, Filiz and Theegarten, Dirk and Stenzinger, Albrecht and Darwiche, Kaid and Koschel, Dirk and Herth, Felix and Bölükbas, Servet and Winter, Hauke and Weykamp, Fabian and Wermke, Martin and Stuschke, Martin and Plönes, Till and Thomas, Michael and Schuler, Martin and Christopoulos, Petros},
title = {Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome},
journal = {International Journal of Cancer},
year = {2025},
volume = {156},
number = {4},
pages = {776--787},
doi = {10.1002/ijc.35199}
}
EUVIMED